ProVise Management Group LLC Purchases 8,554 Shares of Sanofi (NASDAQ:SNY)

ProVise Management Group LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 5.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 161,032 shares of the company’s stock after buying an additional 8,554 shares during the period. ProVise Management Group LLC’s holdings in Sanofi were worth $8,008,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Boston Partners boosted its position in Sanofi by 1.9% in the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after buying an additional 245,682 shares in the last quarter. Morgan Stanley boosted its holdings in Sanofi by 4.6% in the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after purchasing an additional 323,968 shares during the period. Envestnet Asset Management Inc. raised its position in Sanofi by 29.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after purchasing an additional 651,756 shares during the period. Natixis Advisors L.P. increased its position in shares of Sanofi by 15.9% in the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after acquiring an additional 346,563 shares during the period. Finally, Brandes Investment Partners LP boosted its stake in shares of Sanofi by 64.6% during the 4th quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock valued at $88,051,000 after purchasing an additional 694,957 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Price Performance

NASDAQ:SNY traded down $0.46 during trading hours on Friday, hitting $48.54. The company’s stock had a trading volume of 1,423,782 shares, compared to its average volume of 1,988,013. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The company has a market capitalization of $122.79 billion, a PE ratio of 24.45, a PEG ratio of 1.57 and a beta of 0.61. The business’s 50-day moving average is $48.27 and its two-hundred day moving average is $48.20. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The firm had revenue of $11.36 billion for the quarter, compared to analyst estimates of $11.75 billion. As a group, research analysts anticipate that Sanofi will post 4.12 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio is currently 74.37%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.